HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
Court will not hear cross-claim that challenges the PH-ILD indication in the…
Grace Therapeutics Announces Third Fiscal Quarter 2025Financial Results, Provides Business Update
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical…
HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE…
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented…